Grufity logoGrufity logo
StocksFundsSearch Filings

Becton Dickinson and Co Stock Research

BDX

241.12USD-0.65(-0.27%)Market Closed

Market Summary

USD241.12-0.65
Market Closed
-0.27%

BDX Stock Price

BDX RSI Chart

BDX Valuation

Market Cap

71.3B

Price/Earnings (Trailing)

44.09

Price/Sales (Trailing)

3.79

EV/EBITDA

15.66

Price/Free Cashflow

72.01

BDX Price/Sales (Trailing)

BDX Profitability

EBT Margin

9.20%

Return on Equity

6.32%

Return on Assets

3.03%

Free Cashflow Yield

1.39%

BDX Fundamentals

BDX Revenue

Revenue (TTM)

18.8B

Revenue Y/Y

-3.79%

Revenue Q/Q

5.12%

BDX Earnings

Earnings (TTM)

1.6B

Earnings Y/Y

1.32%

Earnings Q/Q

-9.63%

Price Action

52 Week Range

214.27266.70
(Low)(High)

Last 7 days

-4.3%

Last 30 days

-6.7%

Last 90 days

1.7%

Trailing 12 Months

-3.1%

BDX Financial Health

Current Ratio

1.07

BDX Investor Care

Dividend Yield

1.49%

Dividend/Share (TTM)

3.59

Buy Backs (1Y)

2.66%

Diluted EPS (TTM)

5.34

Peers (Alternatives to Becton Dickinson and)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
110.8B
19.0B
-8.78% 16.43%
46.98
6.01
8.73% 30.37%
107.5B
6.4B
4.05% 37.44%
81.96
16.72
8.89% -20.19%
74.1B
13.0B
-0.08% 27.20%
106.12
5.84
7.26% -32.95%
71.3B
18.8B
-6.73% -3.13%
44.09
3.79
-1.96% -15.83%
49.7B
5.5B
-6.18% -16.80%
33.38
9.03
2.68% -3.23%
MID-CAP
7.2T
557.2M
-1.64% 66.40%
82.2K
16.8K
86.42% 730.06%
11.7B
884.6M
7.85% 115.97%
1.8K
13.2
13.08% 200.12%
5.9B
1.1B
-8.20% -19.98%
34.14
5.75
11.20% 53.04%
3.6B
430.0M
-11.89% -12.63%
-34.73
8.45
26.13% 15.73%
1.7B
794.7M
-29.15% -60.56%
-8.43
2.16
7.73% -3556.34%
SMALL-CAP
1.6B
389.0M
-3.76% 82.19%
-10.63
4.18
44.08% 6.96%
1.2B
150.7M
-30.80% 0.49%
-21.65
7.87
40.31% 1.80%
1.1B
814.3M
-20.14% -16.22%
24.47
1.34
6.96% 121.89%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%

Financials for Becton Dickinson and

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue-1.0%18,80918,99918,87019,21919,185
  S&GA Expenses-0.6%4,7234,7504,7094,8514,902
  R&D Expenses-0.5%1,2651,2711,2561,3401,355
Costs and Expenses-1.0%16,57016,73616,58816,95916,969
EBITDA-0.2%4,4034,4105,0525,026-
EBITDA Margin-0.8%0.23*0.23*0.25*0.24*-
Earnings Before Taxes0.2%1,7511,7471,7831,6971,654
EBT Margin-2.7%0.09*0.09*0.11*0.11*-
Interest Expenses4.2%423406398409425
Net Income0.4%1,6171,6111,7791,7561,921
Net Income Margin-10.1%0.08*0.09*0.09*0.09*-
Free Cahsflow-10.4%1,3421,4981,3261,897-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets2.4%54,39453,12952,93453,19954,786
  Current Assets17.3%9,5878,1758,1419,54710,152
    Cash Equivalents237.9%2,0686121,0062,5583,147
  Inventory1.4%3,6563,6043,2243,1633,258
  Net PPE1.7%6,3566,2476,0126,0056,406
  Goodwill0.1%24,78024,76324,62123,96824,096
  Current Liabilities-4.2%7,3047,6257,8117,0806,657
    LT Debt, Non Current12.2%16,01014,26813,88614,68317,584
Shareholder's Equity0.9%25,68925,47225,28225,49324,525
  Retained Earnings1.2%15,56315,38415,15715,08814,416
  Additional Paid-In Capital0.3%19,63919,59019,55319,51119,495
Accumulated Depreciation2.5%6,8486,6796,4026,3996,788
Shares Outstanding0.0%285285---
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-17.2%1,9372,3402,4712,3392,523
  Share Based Compensation-1.2%238241233231231
Cashflow From Investing2.7%-2,754-2,829-3,220-1,896-1,970
Cashflow From Financing-28.1%-943-736-1,329-1,609-
  Dividend Payments1.1%1,1041,0921,0821,0711,061
  Buy Backs-83.3%5003,000---

Risks for BDX

What is the probability of a big loss on BDX?

27.3%


Probability that Becton Dickinson and stock will be more than 20% underwater in next one year

0%


Probability that Becton Dickinson and stock will be more than 30% underwater in next one year.

0%


Probability that Becton Dickinson and stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BDX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Becton Dickinson and was unfortunately bought at previous high price.

Drawdowns

Returns for BDX

Cumulative Returns on BDX

10.9%


10-Year Cumulative Returns

7.2%


7-Year Cumulative Returns

3.4%


5-Year Cumulative Returns

3.4%


3-Year Cumulative Returns

What are the long-term rolling returns for BDX?

FIve years rolling returns for Becton Dickinson and.

Annualized Returns

Which funds bought or sold BDX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-24
Old North State Trust, LLC
unchanged
-
-8,000
310,000
0.22%
2023-05-23
MOUNTAIN PACIFIC INVESTMENT ADVISERS INC/ID
reduced
-0.87
-46,271
1,275,330
0.09%
2023-05-23
Front Row Advisors LLC
added
0.97
-
26,000
0.01%
2023-05-23
Toroso Investments, LLC
added
111
2,068,000
4,012,000
0.07%
2023-05-23
Brookfield Corp /ON/
new
-
7,885,390
7,885,390
0.03%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-
-23,097,900
844,442,000
0.28%
2023-05-22
Arete Wealth Advisors, LLC
sold off
-100
-287,030,000
-
-%
2023-05-22
FDx Advisors, Inc.
unchanged
-
-
1,667,000
0.07%
2023-05-22
PUTNAM INVESTMENTS LLC
added
8.87
417,290
7,403,670
0.01%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-41.79
-22,921,000
31,488,000
0.01%

1–10 of 48

Latest Funds Activity

Are funds buying BDX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BDX
No. of Funds

Becton Dickinson and News

Scene for Dummies: Everything Hollywood Undead
Injection And Infusion-based Drug Delivery Devices Market to ....
Scene for Dummies: Everything Hollywood Undead,
10 hours ago
Zacks Investment Research
Medical Design & Outsourcing
BD explores plastic blood tube recycling.
Medical Design & Outsourcing,
12 days ago

Schedule 13G FIlings of Becton Dickinson and

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
6.7%
18,962,386
SC 13G/A
Feb 09, 2023
vanguard group inc
8.94%
25,421,347
SC 13G/A
Feb 07, 2023
blackrock inc.
8.4%
23,781,609
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
7.0%
20,016,331
SC 13G
Feb 09, 2022
vanguard group inc
8.48%
24,176,366
SC 13G/A
Feb 08, 2022
blackrock inc.
7.5%
21,348,508
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
4.2%
12,347,992
SC 13G/A
Feb 10, 2021
vanguard group inc
8.38%
24,360,444
SC 13G/A
Feb 08, 2021
fmr llc
-
0
SC 13G/A
Feb 05, 2021
blackrock inc.
7.9%
22,926,497
SC 13G/A

BDX Fair Value

Recent SEC filings of Becton Dickinson and

View All Filings
Date Filed Form Type Document
May 25, 2023
SD
SD
May 24, 2023
25-NSE
25-NSE
May 08, 2023
4
Insider Trading
May 08, 2023
4
Insider Trading
May 04, 2023
8-K
Current Report
May 04, 2023
10-Q
Quarterly Report
May 02, 2023
4
Insider Trading
Apr 21, 2023
144
Notice of Insider Sale Intent
Apr 17, 2023
144
Notice of Insider Sale Intent
Apr 06, 2023
4
Insider Trading

Latest Insider Trading transactions for BDX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-01
Quinn Michelle
sold (taxes)
-
-
-99.00
evp and general counsel
2023-04-04
Neal Shana Carol
acquired
-
-
8,229
chief human resources officer
2023-04-04
Neal Shana Carol
sold (taxes)
-
-
-731
chief human resources officer
2023-03-02
Ezell Antoine C
sold (taxes)
-
-
-650
evp, president na & cmo
2023-03-01
Spoerel Thomas J
sold (taxes)
-
-
-35.00
svp,controller&chief acct off
2023-03-01
Garrison Michael David
sold (taxes)
-
-
-193
evp & president medical
2023-03-01
Ezell Antoine C
sold (taxes)
-
-
-418
evp, president na & cmo
2023-02-03
Byrd Richard
sold
-353,261
248
-1,421
evp & president interventional
2023-01-26
Fraser Claire
acquired
-
-
848
-
2023-01-24
LARSEN MARSHALL O
acquired
-
-
848
-

1–10 of 50

Thomas E. Polen
65535
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

BDX Income Statement

2023-03-31
Condensed Consolidated Statements of Income - USD ($)
$ in Millions
3 Months Ended6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenues$ 4,821$ 4,750$ 9,407$ 9,468
Cost of products sold2,5862,6375,0385,135
Selling and administrative expense1,2051,1922,3922,378
Research and development expense337327651641
Acquisition-related integration and restructuring expense622810662
Other operating expense (income), net407(4)
Total Operating Costs and Expenses4,1934,1858,1938,212
Operating Income6285641,2131,256
Interest expense(118)(97)(220)(195)
Interest income102164
Other income (expense), net8(27)1(24)
Income from Continuing Operations Before Income Taxes5294421,0091,041
Income tax provision68524084
Net Income from Continuing Operations460390969958
Income from Discontinued Operations, Net of Tax0640173
Net Income4604549691,131
Preferred stock dividends(23)(23)(45)(45)
Net income applicable to common shareholders$ 438$ 431$ 924$ 1,086
Income from Continuing Operations, Basic (USD per share)$ 1.54$ 1.29$ 3.25$ 3.20
Income from Discontinued Operations, Basic (USD per share)00.2200.61
Basic Earnings per Share (USD per share)1.541.513.253.81
Income from Continuing Operations, Diluted (USD per share)1.531.283.243.18
Income from Discontinued Operations, Diluted (USD per share)00.2200.60
Diluted Earnings per Share (USD per share)1.531.503.243.78
Dividends per Common Share (USD per share)$ 0.91$ 0.87$ 1.82$ 1.74

BDX Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2023
Sep. 30, 2022
Current Assets:  
Cash and equivalents$ 1,981$ 1,006
Restricted cash87153
Short-term investments68
Trade receivables, net2,4132,191
Inventories:  
Materials788707
Work in process428397
Finished products2,4412,120
Inventories3,6563,224
Prepaid expenses and other1,4441,559
Total Current Assets9,5878,141
Property, Plant and Equipment13,20412,415
Less allowances for depreciation and amortization6,8486,402
Property, Plant and Equipment, Net6,3566,012
Goodwill24,78024,621
Developed Technology, Net8,6109,108
Customer Relationships, Net2,5122,683
Other Intangibles, Net555519
Other Assets1,9941,848
Total Assets54,39452,934
Current Liabilities:  
Current debt obligations2,2142,179
Payables, accrued expenses and other current liabilities5,0905,632
Total Current Liabilities7,3047,811
Long-Term Debt16,01013,886
Long-Term Employee Benefit Obligations920902
Deferred Income Taxes and Other Liabilities4,4715,052
Commitments and Contingencies (See Note 5)
Shareholders’ Equity  
Preferred stock22
Common stock — $1 par value; authorized — 640,000,000 shares; issued — 364,639,901 shares in March 31, 2023 and September 30, 2022365365
Capital in excess of par value19,63919,553
Retained earnings15,56315,157
Deferred compensation2423
Treasury stock(8,327)(8,330)
Accumulated other comprehensive loss(1,575)(1,488)
Total Shareholders’ Equity25,68925,282
Total Liabilities and Shareholders’ Equity$ 54,394$ 52,934